论文部分内容阅读
目的探究GDP方案治疗复发难治性非霍奇金淋巴瘤的临床疗效。方法选取27例复发难治性非霍奇金淋巴瘤患者的临床资料进行回顾性分析,所有患者均采用GDP方案进行治疗,即吉西他滨+地塞米松+顺铂联合治疗,观察治疗后患者临床疗效和不良反应情况。结果治疗后,27例患者中完全缓解6例,部分缓解12例,稳定5例,进展4例,治疗总有效率为66.7%;其中2例患者出现恶心呕吐,1例患者出现轻度消化道反应,经对症治疗后得到有效缓解,不影响整体治疗效果。结论采用GDP方案治疗复发难治性非霍奇金淋巴瘤,能够有效改善或缓解患者临床症状,治疗总有效率高,患者不良反应少,治疗效果显著,值得临床推广应用。
Objective To explore the clinical efficacy of GDP regimen in the treatment of relapsed and refractory non-Hodgkin’s lymphoma. Methods The clinical data of 27 patients with recurrent refractory non-Hodgkin’s lymphoma were retrospectively analyzed. All patients were treated with GDP regimen, that is, gemcitabine + dexamethasone + cisplatin combined treatment, and the clinical efficacy was observed after treatment And adverse reactions. Results After treatment, 6 patients were completely relieved in 27 patients, 12 patients were partially relieved, 5 patients were stable, 4 patients progressed, and the total effective rate was 66.7%. Two patients had nausea and vomiting and one patient had mild digestive tract Response, effective treatment after symptomatic relief, does not affect the overall treatment effect. Conclusion The treatment of refractory non-Hodgkin’s lymphoma with GDP regimen can effectively improve or relieve the clinical symptoms of patients. The total effective rate of treatment is high, patients have few adverse reactions, and the treatment effect is significant, which is worthy of clinical application.